BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Maraone A, Tarsitani L, Pinucci I, Pasquini M. Antiglutamatergic agents for obsessive-compulsive disorder: Where are we now and what are possible future prospects? World J Psychiatr 2021; 11(9): 568-580 [PMID: 34631461 DOI: 10.5498/wjp.v11.i9.568]
URL: https://www.wjgnet.com/2220-3206/full/v11/i9/568.htm
Number Citing Articles
1
Riccardo Gennari, Nicole Capretti, Danial Daroui, Sergio Terracina, Lorenzo Martellone, Andrea Mastrostefano, Giuseppe Greco. The Potential Use of Selective Serotonin Reuptake Inhibitor Therapy for Gambling Disorders Associated with Impulse-Control DisordersTargets 2026; 4(2) doi: 10.3390/targets4020019
2
Hasan Mirzazadeh, Younes Ghaeminia, Amin Mohamad Niaei, Mohammadsadegh Kamran, Leila Razeghian Jahromi, Reza Moshfeghinia. Memantine augmentation of escitalopram in treatment of executive function among patients with obsessive-compulsive disorder (OCD): a double-blind placebo-controlled randomized clinical trialBMC Psychiatry 2025; 25(1) doi: 10.1186/s12888-025-06856-7
3
Júlia Grigorini Mori Ayub, Cristina Luz Tosta, Breno Lopes Macedo, Tattyanna Fernandes Barreto, Lorena Martins Lopes, Maria Paula dos Santos Fracalossi, Roberto Andreatini, Vanessa Beijamini. S-ketamine exerts sex- and dose-dependent anti-compulsive-like effect as monotherapy or in augmentation to fluoxetineEuropean Journal of Pharmacology 2022; 937 doi: 10.1016/j.ejphar.2022.175382
4
Jacob Blaney, Sanjana Konda, Latha Ganti. Bibliometric analysis of OCD prevalence in youth populations of developing countriesCambridge Prisms: Global Mental Health 2025; 12 doi: 10.1017/gmh.2025.12
5
Rakesh Sahu. Exploring Biomarkers and Contributing Factors in Obsessive-Compulsive Disorder: HypothesisAcademic Bulletin of Mental Health 2024; 2 doi: 10.25259/ABMH_12_2024
6
Mohammad Ali Salehinejad, Amir-Homayun Hallajian, Miles Wischnewski, André Aleman, Marom Bikson, Daniel M. Blumberger, Jérôme Brunelin, Andre R. Brunoni, Zafiris J. Daskalakis, Stevan Nikolin, Frank Padberg, Alexander T. Sack, Michael Siniatchkin, Odile A. van den Heuvel, Zahra Vaziri, Carmelo M. Vicario, Trevor W. Robbins, Michael A. Nitsche. Transcranial electrical stimulation for the treatment of obsessive–compulsive disorder: a triple meta-analysisNature Mental Health 2026; 4(4) doi: 10.1038/s44220-026-00590-z
7
Annalisa Maraone, Alessandro Trebbastoni, Antonella Di Vita, Fabrizia D'Antonio, Carlo De Lena, Massimo Pasquini. Memantine for Refractory Obsessive-Compulsive Disorder: Protocol for a Pragmatic, Double-blind, Randomized, Parallel-Group, Placebo-Controlled, Monocenter TrialJMIR Research Protocols 2023; 12 doi: 10.2196/39223
8
Behnaz Bakhshinejad, Abdolreza Sabahi, Tania Dehesh, Zarrin Sarhadynejad, Mehrnaz Mehrabani, Mahdiyeh Khazaneha, Mehrzad Mehrbani, Mitra Mehrabani. Efficacy of the herbal product of Cuscuta campestris Yunck. and Polypodium vulgare L. in patients with obsessive-compulsive disorder: A triple-blind clinical trialJournal of Ethnopharmacology 2026; 354 doi: 10.1016/j.jep.2025.120452
9
OBSESSIVE COMPULSIVE DISORDER - A REVIEW OF TREATMENT METHODSInternational Journal of Innovative Technologies in Social Science 2025; 3(3(47)) doi: 10.31435/ijitss.3(47).2025.3714
10
Sydney Raboin. Visualizing victory: the role of imagery in empowering athletes battling obsessive-compulsive disorderJournal of Imagery Research in Sport and Physical Activity 2024; 19(s1) doi: 10.1515/jirspa-2024-0006
11
Ayush Pandey, Rajat Sharma, Sonali Dixit, Shashank Tripathi. The effect of adjuvant treatment in obsessive compulsive disorder patients: A systematic review and meta-analysisJournal of Family Medicine and Primary Care 2025; 14(12) doi: 10.4103/jfmpc.jfmpc_281_25
12
Sam Rashkovich, Ganeev Singh, Eric Hollander. Beyond symptom reduction: targeting cognitive deficits in obsessive-compulsive disorder treatmentInternational Clinical Psychopharmacology 2026; 41(1) doi: 10.1097/YIC.0000000000000603
13
Rituparna Maiti, Archana Mishra, Anand Srinivasan, Biswa Ranjan Mishra. Pharmacological augmentation of serotonin reuptake inhibitors in patients with obsessive–compulsive disorder: A network meta‐analysisActa Psychiatrica Scandinavica 2023; 148(1) doi: 10.1111/acps.13568